HEPA

Insider Trades

Name	Value	Action	Price	Current Price
LoPriore Vincent SDirector, 10 Percent Owner, Officer: Executive Chairman $200k5M shares BuyApr 21, 2026 $0.04 --
Appajosyula SireeshDirector $50k1.3M shares BuyApr 21, 2026 $0.04 --
LoPriore Vincent SDirector, 10 Percent Owner, Officer: Executive Chairman $50k1.3M shares BuyApr 21, 2026 $0.04 --
Purcell Michael J.Director $50k1.3M shares BuyApr 21, 2026 $0.04 --
Stetz Gary S.Director, Officer: Interim CEO $50k1.3M shares BuyApr 21, 2026 $0.04 --

News

defenseworld.netMusclePharm (OTCMKTS:MSLP) & Hepion Pharmaceuticals (NASDAQ:HEPA) Critical Contrastdefenseworld.netApr 3

Trade HEPA

About Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.

CEO: Gary S. Stetz
IPO Date: Feb 10, 2014

Market Data

Open: $0.0501
High: $0.06
Low: $0.0501
Volume: 386
Avg Volume: 22.2K
52W High: $0.25
52W Low: $0.033

Valuation

Market Cap: $699k
Enterprise Value: $-1.9M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-3.3M
Revenue: $0
Net Income: $-8.3M
Cash: $1.8M
Debt: $54k

Events

EarningsSep 2

EPS est. -190